PatientsVille.com Logo


Benign Medical Research Studies

Up-to-date List of Benign Medical Research Studies

What Research is Being Done?

A clinical study involves research using human volunteers (also called participants) that is intended to add to medical knowledge. There are two main types of clinical studies: clinical trials (also called interventional studies) and observational studies. Following list includes both interventional and observational studies.

Latest Benign Medical Research Studies

Rank Status Study
1 Recruiting Use of Metal Stents on Benign Esophageal Lesions
Condition: Benign Esophageal Lesions
Intervention: Procedure: Endoscopy
Outcome Measure: Successful stenting of Benign esophageal lesions
2 Recruiting Evaluation of the Use of Metal Stents as Part of the Treatment of Benign Biliary Strictures
Condition: Benign Biliary Strictures
Intervention: Procedure: Endoscopic Retrograde Cholangiopancreatography (ERCP)
Outcome Measure: Benign Biliary Strictures resolution
3 Recruiting Prostatic Artery Embolization (PAE) for Treatment of Benign Prostatic Hyperplasia (BPH)
Condition: Benign Prostatic Hyperplasia (BPH)
Intervention: Device: Prostate Artery Embolization
Outcome Measures: The Primary Objective is to evaluate the safety of prostate artery embolization (PAE) for the treatment of lower urinary tract symptoms (LUTS) attributed to Benign prostatic hyperplasia (BPH).;   Change in International Prostate Symptom Score (IPSS);   Change in quality of life (QOL) bother question;   Change in Benign prostatic hyperplasia (BPH) impact index;   Change in Qmax (peak and total void volume at each follow‐up visit)
4 Recruiting Covered Metallic Stents for First-Line Treatment of Benign Bile Duct Strictures
Condition: Benign Bile Duct Strictures
Interventions: Device: Fully covered Metallic Stent;   Device: Plastic Stent
Outcome Measures: Late Clinical Success;   Technical success;   Early clinical success;   Cost analysis;   Complication rates;   Stent-associated ductal changes
5 Recruiting Diagnostic Accuracy of Ultrasonography in Detecting Benign Radiolucent Lesions
Condition: Benign Radiolucent Lesions
Outcome Measures: Lesion Contents;   3D measurements of the lesion
6 Recruiting Efficacy and Safety of Silodosin on Nocturia for Patients With Benign Prostatic Hyperplasia
Conditions: Nocturia;   Benign Prostatic Hyperplasia
Interventions: Drug: Silodosin;   Other: Laboratory tests;   Other: 3-days voiding diary;   Other: 12 weeks
Outcome Measures: Incidence of nocturia;   Mean change in International Prostate Symptom Score(IPSS) from baseline;   Mean change in Quality of Life(QoL) scores from baseline;   Mean change in Overactive Bladder Symptom Score(OABSS) from baseline;   Mean change in International Consultation on Incontinence modular Questionnaire-Nocturia(ICIQ-N) from baseline;   Mean change in Questions 3, 5 and 6 (voiding symptoms) of IPSS from baseline;   Mean change in Question 1 (postvoiding symptoms) of IPSS from baseline;   Mean change in Questions 2, 4 and 7 (storage symptoms) from baseline;   Ratio of subjects with ≥ 25% decrease in incidence of nocturia;   Ratio of subjects with ≥ 25% decrease in IPSS
7 Recruiting Prostate Embolization for Benign Prostatic Hyperplasia
Condition: Benign Prostatic Hyperplasia
Interventions: Procedure: Prostatic Embolization;   Drug: Embosphere® Microspheres
Outcome Measures: Evidence of bladder or rectal ischemic injury;   Detection of bladder or rectal ischemic injury;   Detection of a bladder or rectal ischemic injury;   Improvement in the International Prostate Symptom Score (IPSS);   Improvement in the International Index of Erectile Function (IIEF-5);   Improvement in Uroflowmetry post embolization;   Prostate volume compared to a pre and post embolization;   Serum PSA;   Post-procedure pain;   Procedure time and radiation parameters;   Percentage of prostate tissue devascularized, based on contrast-enhanced MRI.
8 Recruiting Comparison Between Alpha Blocker Monotherapy and 5ARI Monotherapy Following Combination Therapy in Benign Prostatic Hyperplasia (BPH)
Condition: Benign Prostatic Hyperplasia
Interventions: Drug: combination therapy;   Drug: alpha blocker monotherapy;   Drug: 5 alpha reductase inhibitor monotherapy
Outcome Measures: Numeric change of IPS and Numeric change of IPSS total score;   Changes in patients' symptom questionnaires : IPSS, ICIQ male LUTS;   Changes in urodynamic parameters : maximal flow rate and PVR;   change in finding of TRUS;   Numeric Change and percent change in PSA;   safety evaluation : incidence and severity of adverse events
9 Recruiting Safety and Initial Efficacy Study of the Vortx Rx for Treatment of Benign Prostatic Hyperplasia (US)
Condition: Benign Prostatic Hyperplasia (BPH)
Intervention: Device: Vortx Rx - Histotripsy BPH Device
Outcome Measures: Safety of the Vortx Rx for treatment of symptomatic BPH;   Initial prostate histotripsy treatment efficacy
10 Recruiting Prognostic Value of the Urinary Nerve Growth Factor in the Patients With Benign Prostatic Hyperplasia
Conditions: Benign Prostatic Hypertrophy With Outflow Obstruction;   Overactive Detrusor
Interventions: Procedure: Holmium Laser Enucleation of the Prostate (HoLEP);   Device: Holmium laser enucleation system and morcellator
Outcome Measures: Difference in the baseline urinary NGF level between patients with and without detrusor overactivity at 6 months after HoLEP procedure;   Difference in the IPSS (International Prostate Symptom Score) and uroflowmetry results between the patients with or without detrusor overactivity
11 Not yet recruiting Effectiveness and Safety of Moxibustion Therapy for Benign Prostate Hyperplasia With Lower Urinary Tract Syndrome
Conditions: Moxibustion;   BPH;   Benign Prostatic Hyperplasia;   Benign Prostatic Hypertrophy;   Lower Urinary Tract Symptom
Intervention: Procedure: Moxibustion
Outcome Measures: International prostate symptom score (IPSS) at 4 weeks;   Patient's global impression of change (PGIC);   The Short Form (36) Health Survey (SF-36);   Maximum flow rate by uroflowmetry (Qmax);   Post-voiding residual urine in bladder (PVR);   International Prostate Symptom Score (IPSS)
12 Recruiting Efficacy and Safety of S-Equol on Men With Benign Prostatic Hyperplasia
Condition: Benign Prostatic Hyperplasia
Interventions: Drug: S-equol;   Drug: Placebo
Outcome Measures: To evaluate the change from baseline in prostate specific antigen concentration after 4 weeks of treatment with 3 dose levels of S-equol and placebo.;   To assess the safety and acceptability of S-equol in men with Benign prostatic hyperplasia.
13 Recruiting Effectiveness of the Epley Manoeuvre Performed in Primary Care to Treat Benign Paroxysmal Positional Vertigo
Condition: Benign Positional Paroxysmal Vertigo
14 Not yet recruiting Clinical Trial of Prostatic Arterial Embolization Versus a Sham Procedure to Treat Benign Prostatic Hyperplasia
Conditions: Prostatic Hyperplasia, Benign;   Prostatic Hypertrophy, Benign;   Genital Diseases, Male;   Lower Urinary Tract Symptoms;   Prostatic Diseases
Interventions: Procedure: Prostatic Arterial Embolization;   Procedure: Sham procedure
Outcome Measures: Change from baseline in the International Prostate Symptom Score;   Disease specific quality of life question of the International Prostate Symptom Score
15 Recruiting Bupivacaine for Benign Headache in the ED
Condition: Benign Headache
Interventions: Drug: 0.5% bupivacaine;   Drug: Standard Care
Outcome Measures: Length of stay;   Incidence of immediate and post-discharge complications.;   Symptomatic relief of headache
16 Recruiting Efficacy of Vitamin D and Calcium Supplementation on the Prevention of Recurrences in BPPV
Condition: Benign Paroxysmal Positional Vertigo
Intervention: Drug: 400IU cholecalciferol and 500mg of elemental calcium as calcium carbonate
Outcome Measures: Recurrence rate of Benign paroxysmal positional vertigo;   Changes in serum 25-hydroxy vitamin D level;   Falling frequency;   Fracture frequency;   Quality of life
17 Recruiting Clinical Trial of Safety and Efficiency of Afalaza in Patients With Symptoms of Benign Prostatic Hyperplasia and Risk of Progression
Condition: Benign Prostatic Hyperplasia
Interventions: Drug: Afalaza;   Drug: Placebo
Outcome Measures: Change in total IPSS scores (International Prostate Symptome Score) after 1, 3, 6 and 12 months compared to baseline.;   Dynamics of irritative symptoms evaluated by IPSS (International Prostate Symptome Score) after 1, 3, 6 and 12 months compared to baseline
18 Recruiting JALYN for Benign Prostatic Hyperplasia (BPH) and Chronic Prostatitis/Chronic Pelvic Pain Syndrome (CP/CPPS)
Conditions: Benign Prostatic Hyperplasia;   Chronic Prostatitis
Interventions: Drug: Jalyn;   Drug: Placebo
Outcome Measures: Chronic Prostatitis Symptom Index (CPSI);   Pain subdomain;   IPSS;   GRA;   Urinary subdomain;   Quality of Life subdomain
19 Recruiting Comparative Study of Robotic, Laparoscopic and Open Surgery for Enucleation of Benign Pancreatic Neoplasms
Condition: Pancreatic Neuroendocrine Tumors
Interventions: Procedure: Robotic surgery;   Procedure: Laparoscopic surgery;   Procedure: Open surgery
Outcome Measures: Pancreatic fistula rate;   Mortality rate
20 Recruiting Treatment of Posterior Canal Type of Benign Paroxysmal Positional Vertigo
Condition: Benign Paroxysmal Positional Vertigo (BPPV)
Intervention: Procedure: Canalith repositioning maneuver
Outcome Measure: efficacy of repositioning maneuvers for treating PC-BPPV

These studies may lead to new treatments and are adding insight into Benign etiology and treatment.

A major focus of Benign research is the development of new drugs and other treatment options. Studies seek to identify new drugs to treat various related disorders and to find safer, more effective doses for medications already being used. Other research is aimed at identifying receptors or drug targets.

Discuss Benign